Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. März 2026 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Commercially Launches Precise MRD with Select Community Oncologists

Myriad Genetics announces the launch of the Precise MRD test with a select number of oncology practices for patients with breast cancer.
24. Februar 2026 09:00 ET | Quelle: Myriad Genetics, Inc.

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Data presented at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests.
23. Februar 2026 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Myriad Genetics reports fourth quarter and full-year 2025 financial results; reiterates 2026 financial guidance reflecting strengthened execution.
19. Februar 2026 09:15 ET | Quelle: Myriad Genetics, Inc.

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Myriad Genetics announced the publication of the analytical validation of the FirstGene® Multiple Prenatal Screen in Clinical Chemistry.
16. Februar 2026 16:15 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Myriad will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026.